A first safety study of CAR-T cells given into the brain for glioblastoma that came back
Original title: Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a first, small safety test in people, so it is years away from being something you can get.
The short version
In a small first study, immune cells were put right into the brain, and most people handled it with only mild side effects.
What was studied. Fifteen adults with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that had come back took part in a phase 1 trial. This is the first, smallest kind of study in people, and it mainly checks safety. Doctors took each person's own T cells, changed them to target a marker called B7-H3, and infused them straight into the brain. The group got 72 infusions in all, and 13 people had repeat infusions.
What they found. The treatment was tolerated well. No dose was found to be too toxic to give. Side effects were common but mostly mild, including a fever-like immune reaction in 86.7% of people, a fast heartbeat in 53.3%, vomiting in 53.3%, high blood pressure in 53.3%, and raised pressure inside the skull in 46.7%. Three people had serious side effects rated grade 3: raised pressure inside the skull, a seizure, and reduced alertness. Two of those three happened at the highest dose. Disease was held steady or better in 8 of 14 people whose tumors could be measured, and one person had their tumor disappear and stay gone through the latest check. The 12-month survival rate was 66.7%.
What this means, and what it doesn't
What it could mean: This suggests the approach can be given into the brain without unmanageable harm, at least in a small group. Some people saw their tumor stay stable, and one had it go away. That is a reason to keep testing it. It does not tell us yet whether this helps people live longer than current care.
What it doesn't mean: This is not a cure, and it is not a treatment you can ask for at your clinic. It was a phase 1 trial, the earliest stage of testing in people. Fifteen people is a very small group, and there was no comparison group getting other care. Early results like these often look better than what larger trials later show. The researchers say the next step is a larger phase 2 study. That takes years, and it may not work out.
Source: PubMed, August 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.